These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 21592110)

  • 1. Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease.
    Vichinsky E; Bernaudin F; Forni GL; Gardner R; Hassell K; Heeney MM; Inusa B; Kutlar A; Lane P; Mathias L; Porter J; Tebbi C; Wilson F; Griffel L; Deng W; Giannone V; Coates T
    Br J Haematol; 2011 Aug; 154(3):387-97. PubMed ID: 21592110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
    Vichinsky E; Torres M; Minniti CP; Barrette S; Habr D; Zhang Y; Files B;
    Am J Hematol; 2013 Dec; 88(12):1068-73. PubMed ID: 23946212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
    Vichinsky E; Onyekwere O; Porter J; Swerdlow P; Eckman J; Lane P; Files B; Hassell K; Kelly P; Wilson F; Bernaudin F; Forni GL; Okpala I; Ressayre-Djaffer C; Alberti D; Holland J; Marks P; Fung E; Fischer R; Mueller BU; Coates T;
    Br J Haematol; 2007 Feb; 136(3):501-8. PubMed ID: 17233848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deferasirox for managing transfusional iron overload in people with sickle cell disease.
    Meerpohl JJ; Antes G; Rücker G; Fleeman N; Niemeyer C; Bassler D
    Cochrane Database Syst Rev; 2010 Aug; (8):CD007477. PubMed ID: 20687088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deferasirox for managing iron overload in people with thalassaemia.
    Bollig C; Schell LK; Rücker G; Allert R; Motschall E; Niemeyer CM; Bassler D; Meerpohl JJ
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD007476. PubMed ID: 28809446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.
    Porter JB; Elalfy MS; Taher AT; Aydinok Y; Chan LL; Lee SH; Sutcharitchan P; Habr D; Martin N; El-Beshlawy A
    Ann Hematol; 2013 Jan; 92(2):211-9. PubMed ID: 23086508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload.
    Taher A; Cappellini MD; Vichinsky E; Galanello R; Piga A; Lawniczek T; Clark J; Habr D; Porter JB
    Br J Haematol; 2009 Dec; 147(5):752-9. PubMed ID: 19764988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.
    Cappellini MD; Bejaoui M; Agaoglu L; Canatan D; Capra M; Cohen A; Drelichman G; Economou M; Fattoum S; Kattamis A; Kilinc Y; Perrotta S; Piga A; Porter JB; Griffel L; Dong V; Clark J; Aydinok Y
    Blood; 2011 Jul; 118(4):884-93. PubMed ID: 21628399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload.
    Cappellini MD; Taher A
    Expert Opin Pharmacother; 2008 Sep; 9(13):2391-402. PubMed ID: 18710363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy and safety of deferasirox.
    Cappellini MD
    Blood Rev; 2008 Dec; 22 Suppl 2():S35-41. PubMed ID: 19059055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine.
    Pennell DJ; Porter JB; Piga A; Lai YR; El-Beshlawy A; Elalfy M; Yesilipek A; Kilinç Y; Habr D; Musallam KM; Shen J; Aydinok Y;
    Am J Hematol; 2015 Feb; 90(2):91-6. PubMed ID: 25345697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Fisher SA; Brunskill SJ; Doree C; Gooding S; Chowdhury O; Roberts DJ
    Cochrane Database Syst Rev; 2013 Aug; 2013(8):CD004450. PubMed ID: 23963793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK
    Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iranian experience of deferasirox (Exjade(®)) in transfusion-dependent patients with iron overload: what is the most effective dose based on serum ferritin levels?
    Karimi M; Azarkeivan A; Zareifar S; Cohan N; Bordbar MR; Haghpanah S
    Hematology; 2012 Nov; 17(6):367-71. PubMed ID: 23168076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study.
    Taher A; El-Beshlawy A; Elalfy MS; Al Zir K; Daar S; Habr D; Kriemler-Krahn U; Hmissi A; Al Jefri A
    Eur J Haematol; 2009 Jun; 82(6):458-65. PubMed ID: 19187278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 3-year study of deferasirox therapy in sickle cell disease patients in Basra, Southern Iraq.
    Mohsin AM; Hassan MK
    Niger J Clin Pract; 2018 Jun; 21(6):735-742. PubMed ID: 29888721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange.
    Gattermann N; Jarisch A; Schlag R; Blumenstengel K; Goebeler M; Groschek M; Losem C; Procaccianti M; Junkes A; Leismann O; Germing U
    Eur J Haematol; 2012 Mar; 88(3):260-8. PubMed ID: 22023452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical application of deferasirox: practical patient management.
    Vichinsky E
    Am J Hematol; 2008 May; 83(5):398-402. PubMed ID: 18058997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.
    Jordan LB; Vekeman F; Sengupta A; Corral M; Guo A; Duh MS
    J Clin Pharm Ther; 2012 Apr; 37(2):173-81. PubMed ID: 21592159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.